Rosuvastatin

Oral lipid-lowering drugs were purchased as follows: atorvastatin from Nipro (Osaka, Japan), rosuvastatin from Tokyo Chemical Industry (Tokyo, Japan), probucol from Alfresa Pharma Corp. (Osaka, Japan), and ezetimibe from Nihon Pharmaceutical Industry (Tokyo, Japan). Atorvastatin (2 mg/kg), rosuvastatin (1 mg/kg), probucol (45 mg/kg) or ezetimibe (0.5 mg/kg) was included in a piece of banana that was consumed by the LDLR KO monkeys once a day for 4 weeks. An anti-PCSK9 antibody, evolocumab, was purchased from Amgen (Thousand Oaks, CA, USA). One subcutaneous injection of evolocumab (6 mg/kg) was performed in LDLR KO monkeys. Blood samples were collected from the monkeys before and 2 and 4 weeks after the administration of statins, probucol and ezetimibe, and before and 1 and 2 weeks after the administration of evolocumab. Plasma total cholesterol concentration was measured by the LabAssay Cholesterol kit (Fujifilm Wako), and plasma LDL and HDL concentrations were outsourced to Oriental Yeast.

Human AML cell lines, Molm14, and the relatively cytarabine‐resistant cell lines OCI‐AML3 and THP‐1²⁷ (Figure S2) were obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen. All cells were cultured in RPMI 1640 medium with 10% FBS and 100 U/mL streptomycin/penicillin in a humidified atmosphere at 37°C and 5% CO₂. Quizartinib (AC220) and cytarabine were purchased from Selleck Chemicals, dissolved in dimethyl sulphoxide (DMSO) at stock concentrations of 10 mmol/L and stored at −80°C. Rosuvastatin was purchased from Tokyo Chemical Industry. Pravastatin, terbinafine, bempedoic acid and zoledronic acid were purchased from Selleck Chemicals. Unless otherwise indicated, all drugs were dissolved in DMSO at stock concentrations of 100 mmol/L and stored at −20°C. Fluorescein isothiocyanate‐Annexin V antibody and propidium iodide were purchased from BD Pharmingen and Sigma‐Aldrich.